Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With Lu-177-PSMA-617

摘要

An 80-year-old patient with castrate-resistant prostate cancer presented to our department for PSMA imaging because of a rising prostatespecific antigen (PSA) level. The tumorwas diagnosed in 2004. GnRh analog was the only treatment the patient received. Two cycles of Lu-177-PSMA-617 were performed with a 2-month interval in between. Ten months after finishing with 2 cycles of Lu-PSMA therapy, we noticed a continuous falling PSA level and a decreasing tumor spread in the PET/CT imaging just under the hormone therapy.